Cotización Recordati - REC

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Último Precio

51.50

Postura de Compra

51.50

Postura de Venta

51.55

Volume Operado de la Acción

94,090

50.90 Rango del Día 51.55

46.49 Rango de 52 semanas 54.80

Capitalización de Mercado [m]

10.576B

Precio Anterior

51.15

Precio de Apertura

51.20

Hora

201

51.5

Última hora de negociación

06:17:28

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

271,999

Acciones en circulación

205,358,104

Rendimiento del Dividendo

2.39%

Ratio Precio/Utilidad

27.57

Beneficio por acción (BPA)

1.9

turnover

2.07B

Beneficio neto

389.21M

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

www.recordati.it

Sede

Milan, Lombardy, Ita

Fundado

1926

Recordati SpA is listed in the Pharmaceutical Preparations sector of the Italian Stock Exchange with ticker REC. The last closing price for Recordati was 51.15 €. Over the last year, Recordati shares have traded in a share price range of 46.49 € to 54.80 €.

Recordati currently has 205,358,104 shares in issue. The market capitalisation of Recordati is 10.50 € billion. Recordati has a price to earnings ratio (PE ratio) of 27.57.

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5% Consolidated net revenue of € 1,743.1 million in the...

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi...

Recordati Rare Diseases annonce la publication dans The Journal of Clinical Endocrinology & Metabolism des résultats de l’étude de Phase III LINC 4 confirmant l'efficacité et la tolérance d’Isturisa® (osilodrostat)...

L’étude LINC 4 a démontré la supériorité d’Isturisa® (osilodrostat) comparé au placebo pour normaliser le cortisol au cours de la phase de 12 semaines en double aveugle, randomisée de l’étude (77...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO L’EFFICACIA E LA SICUREZZA DI ISTURISA® (OSILODROSTAT) PER...

Recordati Rare Diseases: Positive Results From the Phase III LINC 4 Study Presented Today at the Endocrine Society’s Annual...

Statistically significant results from the pivotal Phase III LINC 4 study demonstrate that Isturisa® (osilodrostat) provides rapid and sustained normalisation of mean urinary free cortisol levels...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0.1	0.194552529183	51.4	52.2	50.8	282945	51.63376895	DE
4	-0.7	-1.34099616858	52.2	54.1	49.48	288676	51.34765516	DE
12	0.95	1.87932739862	50.55	54.8	48.58	271999	51.81485243	DE
26	2.08	4.20882233913	49.42	54.8	47.38	245328	51.03646761	DE
52	4.71	10.066253473	46.79	54.8	46.49	238418	50.58964977	DE
156	-2.3	-4.2750929368	53.8	56.96	34.52	234939	45.6928796	DE
260	16.02	45.1521984216	35.48	57.9	28.26	282538	44.85442312	DE

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
BEBeghelli SPA	0.329 € (42.42%)	5.29M
BBastogi Spa	0.44 € (10.00%)	84.08k
LASIASIA	2.66 € (9.92%)	4k
MNLMonnalisa SPA	0.84 € (7.69%)	53.87k
1HLHecla Mining Co	5.602 € (6.75%)	1.7k
WICC24International Care Company	0.06 € (-29.33%)	110
WTFINTrevi Finanziaria Industriale Spa	1.0502 € (-20.44%)	127
WGML25GM Leather spa	0.0085 € (-19.05%)	117.26k
WERFOLaboratorio Farmaceutico Erfo SPA	0.009 € (-10.00%)	19k
1CMCSAComcast Corp	37.135 € (-9.42%)	16
TITTelecom Italia SpA	0.2424 € (-0.04%)	120.59M
RNRisanamento	0.0287 € (1.77%)	16.8M
ISPIntesa Sanpaolo Spa	3.849 € (0.26%)	16.33M
TITRTelecom Italia	0.2787 € (-0.39%)	13.23M
SPMSaipem Spa	2.475 € (-1.08%)	10.51M